查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001082

老齡化黃斑部病變市場：2026-2032年全球市場預測（按疾病類型、治療方法、基準視力、給藥途徑、分銷管道和最終用戶分類）

Age-related Macular Degeneration Market by Disease Type, Treatment Modality, Baseline Visual Acuity, Route of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年，與老齡化的黃斑部病變市場價值為 115.9 億美元，預計到 2025 年將成長至 124.9 億美元，複合年成長率為 8.10%，到 2032 年將達到 216.3 億美元。

主要市場統計數據
基準年 2024 115.9億美元
預計年份：2025年 124.9億美元
預測年份 2032 216.3億美元
複合年成長率 (%) 8.10%

簡要概述當前臨床、技術和營運趨勢如何重塑老齡化黃斑部病變的治療和策略重點。

老齡化黃斑部病變（ AMD）仍然是眼科研究和臨床治療的核心挑戰，其主要促進因素是人口結構變化和治療方法的進步。治療手段已不再局限於單一治療方法，而是擴展到生物製藥、緩釋裝置、基因療法和先進影像技術，這給臨床醫生、保險公司和製造商帶來了複雜的挑戰。隨著診斷準確性的提高和患者照護的日益整合，相關人員必須在門診、醫院和專科醫療中心層級協調臨床需求與實際運作。

治療方法、診斷技術和數位化護理路徑的創新如何重新定義臨床實務、經營模式和競爭優勢？

老齡化黃斑部病變的治療方法和技術進步正在從根本上重塑臨床路徑和供應商策略。曾經是新生血管疾病治療標準療法的抗血管內皮生長因子（VEGF）藥物，如今與緩釋植入、可更換給藥平台以及旨在減輕治療負擔和提高治療永續性的新型基因治療方法並存。包括高解析度光學同調斷層掃描（OCT）和整合多模態診斷在內的成像技術的進步，正在促進疾病分層並實現早期療育。

評估 2025 年美國關稅上調對眼科醫療保健供應鏈、採購實務和策略製造決策的影響。

美國2025年實施的關稅上調對眼科醫療保健的供應鏈和服務交付產生了連鎖的營運和策略影響。進口零件、醫療設備和某些生物原料關稅的提高，增加了依賴國際製造地生產管瓶、預填充式注射器、給藥系統和專用設備的供應商的接收成本。為此，製造商重新審視了其籌資策略，加快了供應商多元化，並優先考慮認證其他契約製造組織（CMO），以降低單一國家成本衝擊的風險。

將治療領域、給藥途徑、醫療保健環境和分銷管道與臨床導入狀態和策略機會聯繫起來的基於細分的綜合洞察。

市場細分為解讀不同治療領域和通路的臨床導入模式和商業性機會提供了一個框架。基於治療方法，市場分析區分了非藥物療法和藥物干預，其中非藥理學的處置方法進一步細分為雷射療法和動態療法。這種結構突顯了微創治療方案和藥物療法的交叉領域。按藥物類別分類，分析觀點區分了抗VEGF藥物和皮質類固醇，並將抗VEGF藥物進一步細分為阿柏西普、Bevacizumab、布羅盧西珠單抗和雷珠單抗，同時將皮質類固醇分為地塞米松和曲安奈德，從而清晰地展現了基於適應症的治療方法選擇、處方集趨勢和使用情況。

美洲、歐洲、中東和非洲以及亞太地區臨床引入、監管途徑和商業化方法的區域差異。

區域趨勢持續影響美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、監管預期和商業化策略。在美洲，完善的健保報銷體系和玻璃體內注射療法的高普及率凸顯了治療最佳化、用藥依從性策略以及減少就診次數的創新的重要性。醫療整合和一體化醫療網路也影響採購和合約行為。在歐洲、中東和非洲，不同的監管管道和支付模式要求製藥公司開發針對特定區域的證據和適應性定價策略，以確保產品被納入醫保覆蓋範圍並維持盈利。

在老齡化黃斑部病變(AMD) 生態系統中，塑造治療領導地位、交付創新和綜合解決方案的公司的策略行動和夥伴關係模式

在老齡化黃斑部病變(AMD) 生態系統中，企業策略的特徵是產品組合多元化、建立目標明確的夥伴關係，以及投資於先進的製造流程和資料能力。成熟的生物製藥公司透過不斷改進已通過核准的抗 VEGF 藥物，並支持真實世界數據研究，從而保持其領先地位，這些研究為拓展適應症和創新給藥方法奠定了基礎。同時，在緩釋系統和眼科器械領域擁有獨特優勢的公司，正利用策略聯盟，將給藥平台與成熟的生物製藥結合，打造差異化的產品和服務，以滿足臨床醫生和患者減輕治療負擔的需求。

高階主管應採取切實可行的、優先考慮的策略行動，以提高臨床價值、供應彈性、市場進入和商業性差異化。

產業領導企業應採取一系列切實可行的措施，以協調臨床價值、商業性永續性和營運韌性。首先，他們應優先開發緩釋機制和聯合治療，以顯著降低治療頻率，同時維持並改善長期視覺功能。證據包應強調以病人為中心的終點指標和醫療系統資源的利用。其次，他們應透過在全球範圍內認證多家生產合作夥伴，並投資於庫存分析，以降低前置作業時間風險並控制營運資金需求，從而增強供應鏈的柔軟性。

一個穩健的混合方法研究框架，整合了對關鍵相關人員的訪談、二手監管和臨床證據以及情境檢驗，以獲得可操作的見解。

本研究途徑結合了初步研究和對二手資料的全面回顧，以確保研究結果的可靠性和實用性。初步研究包括對眼科醫生、醫院和專科醫療中心的採購經理、銷售部門的高級管理人員以及臨床試驗的主要研究者進行結構化訪談，以了解他們對治療方案引入、運營限制以及與支付方互動等方面的第一手觀點。二級資訊來源包括同行評審的臨床文獻、監管核准文件、臨床試驗註冊資訊和公開文件，以檢驗治療方案、適應症和安全性數據。

全面概述了臨床創新、營運準備和策略挑戰，這些因素對於改善老齡化黃斑部病變。

簡而言之，老齡化黃斑部病變（AMD）的治療格局正處於一個轉折點，治療創新、給藥技術和機構壓力在此交匯，重塑著治療模式。減少治療頻率並滿足黃斑部病變未滿足需求的進展老齡化巨大的臨床前景，但其實現需要協作式證據生成、靈活的商業模式和穩健的供應鏈。積極調整採購慣例、投資於生產靈活性並將證據策略與支付方期望一致的相關人員，將更有能力將科學突破轉化為永續的臨床和商業性價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章老齡化黃斑部病變市場：依疾病類型分類

  • 濕性AMD
  • 乾性酸性礦山排水

第9章：依治療方法老齡化黃斑部病變市場

  • 藥物治療
    • 抗 VEGF 藥物
      • 阿柏西普
      • 雷尼珠單抗
      • Bevacizumab
      • 布羅盧西珠單抗
    • 補體抑制劑
      • 佩格塞塔科計劃
      • 阿巴辛卡普塔德·佩戈爾
    • 蛋白酪氨酸激酶抑制劑
    • 整合素抑制劑
    • 營養補充品
  • 基因治療
  • 動態療法
  • 放射線治療
  • 視覺復健和輔助器具

第10章基準視力分類的老齡化黃斑部病變市場

  • 20/40 或以上
  • 20/50～20/200
  • 少於 20/200

第11章老齡化黃斑部病變市場：依給藥途徑分類

  • 玻璃體內注射
  • 口服
  • 眼藥水

第12章老齡化黃斑部病變市場：依分銷管道分類

  • 網路藥房
  • 物理藥房

第13章老齡化黃斑部病變市場：依最終用戶分類

  • 診所
  • 醫院
  • 專業眼科中心
  • 居家照護設施

第14章老齡化黃斑部病變市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章老齡化黃斑部病變市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章老齡化黃斑部病變市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國老齡化黃斑部病變市場

第18章：中國老齡化黃斑部病變市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Outlook Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market was valued at USD 11.59 billion in 2024 and is projected to grow to USD 12.49 billion in 2025, with a CAGR of 8.10%, reaching USD 21.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.59 billion
Estimated Year [2025] USD 12.49 billion
Forecast Year [2032] USD 21.63 billion
CAGR (%) 8.10%

A concise orientation to current clinical, technological, and operational forces reshaping age-related macular degeneration care and strategic priorities

Age-related macular degeneration remains a central focus for ophthalmic research and clinical care, driven by demographic shifts and evolving therapeutic possibilities. The landscape has expanded beyond single-modality treatments to encompass biologics, sustained-release devices, gene-based interventions, and advanced imaging, creating a complex environment for clinicians, payers, and manufacturers to navigate. As diagnostic precision improves and patient pathways become more integrated, stakeholders must reconcile clinical need with operational realities across outpatient clinics, hospitals, and specialty centers.

Translational advances in molecular biology and drug delivery have shortened development cycles for some therapeutic classes while introducing new regulatory and manufacturing challenges. Concurrently, payer scrutiny and procurement practices have intensified, prompting providers to optimize treatment regimens and care delivery models. For decision-makers, understanding the interplay between therapeutic innovation, clinical adoption, and supply chain resiliency is essential to formulate sustainable strategies that deliver improved visual outcomes while controlling total cost of care.

This executive summary synthesizes prevailing trends, supply chain dynamics, segmentation insights, regional nuances, and strategic imperatives to enable informed action. The intent is to offer an analytically rigorous yet accessible foundation for senior leaders seeking to prioritize investments, partnerships, and operational changes in the current era of rapid technological and policy-driven shifts.

How converging therapeutic innovations, diagnostics, and digital care pathways are redefining clinical practice, commercial models, and competitive advantage

The therapeutic and technological shifts occurring in age-related macular degeneration are reshaping clinical pathways and vendor strategies in meaningful ways. Anti-VEGF agents, which once defined the standard of care for neovascular disease, now coexist with sustained-release implants, refillable delivery platforms, and emerging gene-based modalities that aim to reduce treatment burden and improve durability. Imaging advances, including higher-resolution optical coherence tomography and integrated multimodal diagnostics, have enhanced disease stratification and enabled earlier interventions.

Artificial intelligence and cloud-enabled workflows are increasingly used to triage referrals, monitor progression remotely, and standardize treatment decision-making across networks. These capabilities are altering care delivery economics by shifting some monitoring activities to community clinics and telemedicine platforms while concentrating procedural interventions within specialty centers. The convergence of real-world evidence and adaptive regulatory pathways has accelerated the translation of innovative devices and biologics, but it has also amplified expectations for post-approval surveillance and outcome-based contracting.

As a result, commercial models are evolving to accommodate value-based arrangements, differentiated pricing for sustained-delivery products, and new partnerships between diagnostic vendors and therapeutic developers. The cumulative effect is a landscape in which clinical effectiveness, operational efficiency, and commercial agility collectively determine competitive positioning.

Assessment of how 2025 tariff escalations in the United States disrupted ophthalmic supply chains, procurement behavior, and strategic manufacturing decisions

The imposition of elevated tariff measures in the United States during 2025 has created a cascade of operational and strategic consequences for the ophthalmic supply chain and service delivery. Higher duties on imported components, devices, and certain biologic inputs elevated landed costs for suppliers who rely on international manufacturing hubs for vials, prefilled syringes, delivery systems, and specialized instrumentation. In response, manufacturers reassessed sourcing strategies, accelerated supplier diversification, and prioritized qualification of alternative contract manufacturing organizations to reduce exposure to single-country cost shocks.

Procurement teams within hospitals and specialty centers began to renegotiate long-term supply agreements and to demand greater price transparency from vendors, which intensified commercial pressure on manufacturers to absorb or offset tariff-related cost increases. Some providers explored changes in inventory management, such as larger safety stocks or staggered purchasing cycles, to buffer against short-term disruption, but these adjustments increased working capital requirements and warehousing needs. In parallel, payers scrutinized reimbursement pathways and utilization patterns more closely, seeking to align reimbursement with overall value and to limit the transference of tariff-induced cost inflation to final service pricing.

The tariff environment also catalyzed conversations about nearshoring and localized production capacity, particularly for high-volume consumables and delivery devices, where scale economics could justify capital investments. Regulatory interplay and lead times for establishing domestic manufacturing, however, constrained the speed at which reshoring could mitigate cost impacts. Consequently, companies that adopted flexible sourcing, hedging strategies, and stronger supplier governance demonstrated greater resilience, while those with concentrated upstream exposure experienced amplified margin pressure and operational strain.

Integrated segmentation-driven insights linking therapeutic classes, delivery pathways, care settings, and distribution channels to clinical adoption and strategic opportunity

Segmentation provides a framework to interpret clinical adoption patterns and commercial opportunity across distinct therapeutic and distribution pathways. Based on Treatment, market analysis differentiates Non-Pharmacological modalities and Pharmacological interventions, with Non-Pharmacological approaches further situated within Laser Therapy and Photodynamic Therapy; this structure highlights where minimally invasive procedural options intersect with drug-based approaches. Based on Drug Class, the analytical lens distinguishes Anti-VEGF agents from Corticosteroids, and further dissects Anti-VEGF into Aflibercept, Bevacizumab, Brolucizumab, and Ranibizumab while categorizing Corticosteroids into Dexamethasone and Triamcinolone, enabling a clear view of therapeutic substitution, formulary dynamics, and label-driven usage.

Based on Type, the segmentation separates Dry and Wet disease pathways to emphasize differences in disease progression, unmet need, and potential for regenerative or complement-targeted strategies. Based on End User, the analysis considers Clinics, Hospitals, and Specialty Ophthalmic Centers as distinct channels of care delivery, each with unique procurement, staffing, and capacity characteristics that shape technology adoption and treatment frequency. Based on Distribution Channel, the study assesses Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways to reflect evolving purchasing behaviors, the rise of digital dispensing models, and implications for cold-chain logistics and patient access.

Together, these segmentation dimensions allow for nuanced interpretation of clinical utilization patterns, capital and operating investment priorities, and the differential impact of policy or reimbursement changes across care settings. By mapping therapeutic innovations to end-user and distribution realities, stakeholders can better anticipate adoption bottlenecks and prioritize interventions that address the most consequential frictions.

Regional nuances in clinical adoption, regulatory pathways, and commercialization approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape clinical practice patterns, regulatory expectations, and commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement systems and high adoption rates of intravitreal therapies have driven an emphasis on treatment optimization, adherence strategies, and innovations that reduce visit frequency; provider consolidation and integrated delivery networks have also influenced procurement and contracting behavior. Across Europe, Middle East & Africa, heterogeneous regulatory pathways and payer models have led manufacturers to pursue localized evidence generation and adaptive pricing arrangements to secure formulary inclusion and maintain profitability.

In the Asia-Pacific region, rapid investment in diagnostic infrastructure, growing clinical trial activity, and increasing demand from aging populations have accelerated uptake of next-generation therapeutics, while a focus on manufacturing scale and cost optimization has made the region central to global supply networks. Cross-region collaboration, such as multinational clinical programs and harmonized regulatory submissions, has become more common as developers seek to shorten time-to-market and align safety monitoring across jurisdictions. Variations in healthcare infrastructure and provider distribution also affect where procedural capacity is concentrated, often requiring differentiated commercial and training strategies for specialty centers versus community clinics.

Understanding these regional nuances is critical for designing phased market entry plans, aligning regulatory dossiers with local evidence needs, and developing channel strategies that reflect payer expectations and provider capabilities within each geography.

Strategic corporate behaviors and partnership models shaping therapeutic leadership, delivery innovations, and integrated offerings in the AMD ecosystem

Corporate strategy in the age-related macular degeneration ecosystem is characterized by a mix of portfolio diversification, targeted partnerships, and investments in advanced manufacturing and data capabilities. Established biopharmaceutical sponsors maintain leadership through iterative improvements to licensed anti-VEGF agents and by sponsoring real-world evidence studies to support label expansions and dosing innovations. Simultaneously, companies with niche capabilities in sustained-delivery systems and ocular devices are leveraging strategic alliances to combine delivery platforms with established biologics, creating differentiated offerings that address clinician and patient demand for reduced treatment burden.

Across the competitive landscape, alliances between therapeutic developers, contract manufacturers, and diagnostic vendors have increased, reflecting a recognition that integrated solutions-combining therapy, monitoring, and adherence tools-provide stronger commercial value propositions. Investment activity has favored firms that can demonstrate scalable aseptic manufacturing, robust cold-chain logistics, and regulatory experience in ophthalmic modalities. Additionally, firms pursuing novel mechanisms for geographic atrophy and complement inhibition have attracted attention from investors and partners, underscoring the broader appetite for first-in-class interventions within dry AMD.

Companies that prioritize interoperable data strategies, regulatory planning for global submissions, and flexible commercial models for diverse payer environments are better positioned to capture opportunities. At the same time, market entrants must navigate pricing scrutiny and evidentiary expectations, making strategic collaborations and selective evidence generation crucial to commercial success.

Practical and prioritized strategic actions executives should implement to strengthen clinical value, supply resilience, market access, and commercial differentiation

Industry leaders should pursue a set of pragmatic actions to align clinical value with commercial sustainability and operational resilience. First, prioritize development of durable delivery mechanisms and combination approaches that demonstrably reduce treatment frequency while preserving or enhancing long-term visual outcomes; evidence packages should emphasize patient-centric endpoints and health system resource utilization. Second, strengthen supply chain flexibility by qualifying multiple manufacturing partners across geographies and by investing in inventory analytics that reduce lead-time risk while controlling working capital demands.

Third, implement differentiated market access strategies that tailor evidence generation to regional payer expectations and to the specific needs of clinics, hospitals, and specialty centers. This includes negotiation-ready value propositions that reflect real-world treatment pathways and potential savings from reduced visit burden. Fourth, embed digital and diagnostic partnerships into commercial plans to support remote monitoring, adherence programs, and outcome tracking, thereby improving post-launch data collection and enabling outcome-based contracting where feasible. Fifth, foster cross-functional alignment between regulatory, clinical, and commercial teams to streamline global submissions and coordinate post-approval safety monitoring, which will accelerate adoption while maintaining compliance.

Taken together, these actions reduce operational exposure, enhance provider and patient value, and create defensible differentiation in a competitive therapeutic landscape. Executives should sequence investments to balance near-term revenue protection with mid- to long-term capability building that supports sustained leadership.

A robust mixed-methods research framework integrating primary stakeholder interviews, secondary regulatory and clinical evidence, and scenario validation for actionable intelligence

The research approach combined primary qualitative inquiry with comprehensive secondary evidence review to ensure robustness and practical relevance. Primary research included structured interviews with ophthalmologists, procurement leads in hospitals and specialty centers, senior commercial executives, and clinical trial investigators to capture frontline perspectives on treatment adoption, operational constraints, and payer interactions. Secondary sources encompassed peer-reviewed clinical literature, regulatory approval documents, clinical trial registries, and public filings to validate therapeutic profiles, indications, and safety data.

Data synthesis involved cross-validation of interview insights with published evidence and regulatory summaries, supplemented by scenario analysis to explore operational and policy contingencies such as tariff changes or shifts in reimbursement. Segmentation frameworks were developed by mapping therapeutic modalities, drug classes, disease subtypes, end-user settings, and distribution channels to clinical workflows and procurement pathways. Quality assurance measures included reconciliation of conflicting sources, iterative expert review, and transparent documentation of assumptions and inclusion criteria.

Limitations of the methodology include variability in regional reporting standards and the evolving nature of clinical trial outcomes, which necessitates ongoing monitoring of late-stage data. Nonetheless, the triangulated approach provides a reliable foundation for strategic decision-making by integrating real-world clinician perspectives with rigorous secondary evidence and disciplined analytical techniques.

Concluding synthesis linking clinical innovation, operational preparedness, and strategic imperatives required to realize improved outcomes in age-related macular degeneration

In sum, the age-related macular degeneration landscape is at an inflection point where therapeutic innovation, delivery technologies, and systemic pressures intersect to reshape care paradigms. Advances that reduce treatment frequency or address unmet needs in dry AMD offer meaningful clinical promise, but their realization depends on coordinated evidence generation, adaptive commercial models, and resilient supply chains. Stakeholders who proactively adapt procurement practices, invest in manufacturing agility, and align evidence strategies with payer expectations will be better equipped to translate scientific breakthroughs into sustainable clinical and commercial value.

Operationally, the capacity to integrate diagnostics, digital monitoring, and adherence solutions into product offerings will influence adoption trajectories and payer receptivity. Strategically, selective partnerships and targeted regional approaches enable sponsors to balance the demands of regulatory heterogeneity and localized payer systems. As the landscape continues to evolve, ongoing vigilance, flexible planning, and a focus on measurable patient benefit will be essential to converting innovation into improved outcomes across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Age-related Macular Degeneration Market, by Disease Type

  • 8.1. Wet AMD
  • 8.2. Dry AMD

9. Age-related Macular Degeneration Market, by Treatment Modality

  • 9.1. Pharmacotherapy
    • 9.1.1. Anti-VEGF Agents
      • 9.1.1.1. Aflibercept
      • 9.1.1.2. Ranibizumab
      • 9.1.1.3. Bevacizumab
      • 9.1.1.4. Brolucizumab
    • 9.1.2. Complement Inhibitors
      • 9.1.2.1. Pegcetacoplan
      • 9.1.2.2. Avacincaptad Pegol
    • 9.1.3. Tyrosine Kinase Inhibitors
    • 9.1.4. Integrin Inhibitors
    • 9.1.5. Nutritional Supplementation
  • 9.2. Gene Therapy
  • 9.3. Photodynamic Therapy
  • 9.4. Radiotherapy
  • 9.5. Vision Rehabilitation & Assistive Devices

10. Age-related Macular Degeneration Market, by Baseline Visual Acuity

  • 10.1. >= 20/40
  • 10.2. 20/50 To 20/200
  • 10.3. < 20/200

11. Age-related Macular Degeneration Market, by Route of Administration

  • 11.1. Intravitreal Injection
  • 11.2. Oral Administration
  • 11.3. Topical Ophthalmic

12. Age-related Macular Degeneration Market, by Distribution Channel

  • 12.1. Online Pharmacy
  • 12.2. Offline Pharmacy

13. Age-related Macular Degeneration Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Specialty Ophthalmic Centers
  • 13.4. Home Care Settings

14. Age-related Macular Degeneration Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Age-related Macular Degeneration Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Age-related Macular Degeneration Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Age-related Macular Degeneration Market

18. China Age-related Macular Degeneration Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Apellis Pharmaceuticals, Inc.
  • 19.8. Astellas Pharma Inc.
  • 19.9. F. Hoffmann-La Roche AG
  • 19.10. Novartis AG
  • 19.11. Outlook Therapeutics, Inc.
  • 19.12. Regeneron Pharmaceuticals, Inc.
  • 19.13. Samsung Bioepis Co., Ltd.
  • 19.14. Sandoz Group AG
  • 19.15. STADA Arzneimittel AG
  • 19.16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY >= 20/40, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY >= 20/40, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY >= 20/40, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)